Novel Approaches for Preventing or Limiting Events (NAPLES III) trial: Randomised comparison of bivalirudin versus unfractionated heparin in patients at high risk of bleeding undergoing elective coronary stenting throught the femoral approach. Rationale and design

Cardiovascular Drugs and Therapy

Volumn 28, Issue 3, 2014, Pages 273-279

  Briguori, Carlo ^a   Visconti, Gabriella ^a   Focaccio, Amelia ^a   Donahue, Michael ^a   Golia, Bruno ^a   Selvetella, Lucio ^a   Ricciarelli, Bruno ^a  

^a Unit of Reproductive Medicine   (Italy)

Author keywords

Bivalirudin; Bleeding; Outcome; Percutaneous coronary intervention; Unfractionated heparin

Indexed keywords

HEPARIN; HIRULOG; ANTICOAGULANT AGENT; ANTITHROMBIN; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; CONTROLLED STUDY; CORONARY STENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; ELECTIVE SURGERY; METHODOLOGY; PROCEDURES; PROSPECTIVE STUDY; STENT;

ANTICOAGULANTS; ANTITHROMBINS; DOUBLE-BLIND METHOD; ELECTIVE SURGICAL PROCEDURES; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RESEARCH DESIGN; STENTS;

EID: 84903769027     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-014-6518-9     Document Type: Article

References (36)

1. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 accf/aha/scai guideline for percutaneous coronary intervention. A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. J Am Coll Cardiol. 2011;58:e44-e122.
2. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schomig A, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol. 2008;51:690-7. (Pubitemid 351221218)
3. Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, et al. Predictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events (grace). Eur Heart J. 2003;24:1815-23. (Pubitemid 37280247)
4. Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the replace-2 trial. Am J Cardiol. 2007;100:1364-9. (Pubitemid 47576015)
5. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92:930-5. (Pubitemid 37214804)
6. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774-82. (Pubitemid 44268228)
7. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the acuity trial. J Am Coll Cardiol. 2007;49:1362-8. (Pubitemid 46476844)
8. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96:1200-6. (Pubitemid 41505393)
9. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464-76.
10. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (horizons-ami): 1-year results of a randomised controlled trial. Lancet. 2009;374:1149-59.
11. Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the acuity trial. JAMA. 2007;298:2497-506. (Pubitemid 350223536)
12. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary pci in acute myocardial infarction. N Engl J Med. 2008;358:2218-30. (Pubitemid 351724451)
13. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein iib/iiia blockade compared with heparin and planned glycoprotein iib/iiia blockade during percutaneous coronary intervention: Replace-2 randomized trial. JAMA. 2003;289:853-63. (Pubitemid 37430344)
14. National Kidney Foundation. K/doqi clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
15. World Medical Association Inc. Declaration of helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc. 2009;107:403-5.
16. Anello C, O'Neill RT, Dubey S. Multicentre trials: a us regulatory perspective. Stat Methods Med Res. 2005;14:303-18. (Pubitemid 40797030)
17. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of patient-reported outcomes in randomized trials: the consort pro extension. JAMA. 2013;309:814-22.
18. Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, et al. Acute catheterization and urgent intervention triage strategy (acuity) trial: study design and rationale. Am Heart J. 2004;148:764-75.
19. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Circulation. 2012;126:2020-35.
20. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51. (Pubitemid 46685903)
21. Nikolsky E, Mehran R, Dangas G, Fahy M, Na Y, Pocock SJ, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J. 2007;28:1936-45. (Pubitemid 47579535)
22. Rao SV, McCoy LA, Spertus JA, Krone RJ, Singh M, Fitzgerald S, et al. An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: a report using an expanded bleeding definition from the national cardiovascular data registry cathpci registry. JACC Cardiovasc Interv. 2013;6:897-904.
23. Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359:688-96.
24. Tarantini G, Brener SJ, Barioli A, Gratta A, Parodi G, Rossini R, et al. Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a meta-regression analysis of randomized trials. Am Heart J. 2014;167:401-12.e406.
25. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog angioplasty study investigators. N Engl J Med. 1995;333:764-9.
26. Graham MM, Ghali WA, Faris PD, Galbraith PD, Norris CM, Knudtson ML. Survival after coronary revascularization in the elderly. Circulation. 2002;105:2378-84. (Pubitemid 34556389)
27. Robertson T, Kennard ED, Mehta S, Popma JJ, Carrozza Jr JP, King 3rd SB, et al. Influence of gender on in-hospital clinical and angiographic outcomes and on one-year follow-up in the new approaches to coronary intervention (naci) registry. Am J Cardiol. 1997;80:26K-39K. (Pubitemid 28012260)
28. Cox N, Resnic FS, Popma JJ, Simon DI, Eisenhauer AC, Rogers C. Comparison of the risk of vascular complications associated with femoral and radial access coronary catheterization procedures in obese versus nonobese patients. Am J Cardiol. 2004;94:1174-7. (Pubitemid 39424224)
29. Berger PB, Best PJ, Topol EJ, White J, DiBattiste PM, Chan AW, et al. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein iib/iiia inhibitors: the do tirofiban and reopro give similar efficacy outcome (target) trial. Am Heart J. 2005;149:869-75. (Pubitemid 40718884)
30. Mehta SK, Frutkin AD, Lindsey JB, House JA, Spertus JA, Rao SV, et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the national cardiovascular data registry. Circ Cardiovasc Interv. 2009;2:222-9.
31. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010;31:2501-55.
32. Sobel M, Fish WR, Toma N, Luo S, Bird K, Mori K, et al. Heparin modulates integrin function in human platelets. J Vasc Surg. 2001;33:587-94. (Pubitemid 32215610)
33. Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost. 1992;67:639-43.
34. Schulz S, Mehilli J, Ndrepepa G, Neumann FJ, Birkmeier KA, Kufner S, et al. Bivalirudin vs. Unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the isar-react 3 trial. Eur Heart J. 2010;31:582-7.
35. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Mahaffey KW, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol. 2006;47:809-16. (Pubitemid 43243106)
36. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123:2736-47.